RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Launched by GRUPO ARGENTINO DE TRATAMIENTO DE LA LEUCEMIA AGUDA · Feb 26, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Brentuximab Vedotin for patients with Hodgkin Lymphoma (HL) who have not responded to previous treatments or whose HL has come back after treatment. The study takes place in various centers across Argentina and will follow patients who receive a specific type of therapy called autologous stem cell transplant (ASCT) after going through salvage chemotherapy, which is a second chance treatment for their cancer.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of HL that has either not responded to initial treatment or has relapsed. The trial is currently recruiting participants, and it welcomes patients of all genders. If you join, you will be monitored over time to see how well the treatment works and how it affects your health. Your participation would also contribute valuable information to help improve treatment options for others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years or older.
• • All patients with histologically confirmed cHL who are primary refractory or relapse and receive ASCT as part of their salvage therapy.
• • Signature of the form consent for participation in the study.
• Exclusion Criteria:
• • Patients with Relapsed/Refractory cHL not suitable for ASCT.